WINTON GROUP Ltd Makes New Investment in Summit Therapeutics PLC $SMMT

WINTON GROUP Ltd acquired a new stake in Summit Therapeutics PLC (NASDAQ:SMMT) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 64,900 shares of the company’s stock, valued at approximately $1,341,000.

A number of other institutional investors also recently modified their holdings of SMMT. Farther Finance Advisors LLC bought a new stake in shares of Summit Therapeutics in the 3rd quarter worth approximately $1,141,000. Vanguard Group Inc. increased its position in Summit Therapeutics by 31.2% in the third quarter. Vanguard Group Inc. now owns 11,379,728 shares of the company’s stock worth $235,105,000 after buying an additional 2,706,056 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Summit Therapeutics by 774.5% in the second quarter. New York State Common Retirement Fund now owns 256,890 shares of the company’s stock valued at $5,467,000 after buying an additional 227,513 shares during the period. APEIRON CAPITAL Ltd lifted its position in shares of Summit Therapeutics by 9.2% during the 3rd quarter. APEIRON CAPITAL Ltd now owns 1,310,941 shares of the company’s stock valued at $27,084,000 after buying an additional 110,000 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Summit Therapeutics during the 2nd quarter valued at $29,576,000. Institutional investors and hedge funds own 4.61% of the company’s stock.

Wall Street Analysts Forecast Growth

SMMT has been the subject of a number of recent research reports. Barclays upgraded shares of Summit Therapeutics from an “underweight” rating to an “equal weight” rating and lifted their price objective for the company from $16.00 to $18.00 in a research note on Wednesday, December 17th. Wolfe Research initiated coverage on Summit Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Citizens Jmp reiterated a “market outperform” rating and set a $40.00 price objective on shares of Summit Therapeutics in a research note on Friday, January 30th. Zacks Research raised Summit Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.25.

Summit Therapeutics Trading Down 1.6%

SMMT stock opened at $16.07 on Thursday. The stock has a market capitalization of $12.46 billion, a price-to-earnings ratio of -11.08 and a beta of -1.43. The firm’s 50-day moving average price is $16.13 and its two-hundred day moving average price is $18.34. Summit Therapeutics PLC has a 12-month low of $13.83 and a 12-month high of $36.91.

Summit Therapeutics (NASDAQ:SMMT) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.07). Equities analysts predict that Summit Therapeutics PLC will post -0.3 EPS for the current year.

Summit Therapeutics Profile

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.